Product Name:    Fingolimod hydrochloride

Synonyms:    Fingolimod (FTY720) hydrochloride;Fin;limod hydrochloride;fingolimod hydrochloride;FTY720;2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]-1,3-PROPANEDIOL, HYDROCHLORIDE;2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride;Fingolimod HCl

CAS:    162359-56-0

MF:    C19H34ClNO2

MW:    343.93

EINECS:    680-631-1

Product Categories:    Pharmaceuticals;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;API;Other APIs;All Inhibitors;Inhibitors;Metabolites;Pharmaceutical intermediate

Approved by the U.S. FDA in September 2010, fingolimod (also referred to as FTY720) is the first approved oral therapy for the relapsing-remitting form ofmultiple sclerosis (RRMS). Because of fingolimod’s structural resemblance to sphingosine, a metabolite of sphingolipids that constitutes the cell membrane of all eukaryotic cells, it was hypothesized that fingolimod may be affecting sphingolipid metabolism in cells. A series of elegant in vitro and in vivo studies confirmed that fingolimod is converted to (S)-fingolimod phosphate primarily by sphingosine kinase- 2 and that (S)-fingolimod phosphate mediates multiple biological processes by binding to novel GPCR’s referred to as sphingosine-1-phosphate (S1P) receptors. S1P receptors are divided into five subtypes, S1P1–5, which have varying tissue and cellular distribution. S1P1–3 receptors are ubiquitously expressed in the immune, cardiovascular, and central nervous systems, S1P4 is restricted to the hematopoietic system, and S1P5 is mostly localized in the white matter of CNS. S1P1–3 receptors play important roles in endothelial barrier function, maintaining vascular tone, regulating heart rate and allowing for lymphocyte egress fromsecondary lymphoid organs. The functional role of S1P4 is unknown,while the S1P5 receptor is thought to be involved in natural killer cell trafficking and oligodendrocyte function.